Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) has announced a non-binding letter of intent with Nanosoft Polymers, marking an initial step toward negotiating a services agreement to support the development of its exclusively licensed PNKP inhibitor technology, ONC010. The proposed collaboration aims to focus on polymer process development, analytical characterization, formulation optimization, and manufacturing planning activities designed to support future clinical and regulatory development of the oncology candidate.
This move comes as Onco-Innovations works to advance its proprietary technology targeting solid tumors. The company holds an exclusive worldwide license to patented technology that targets solid tumors, and the partnership with Nanosoft Polymers is expected to accelerate the development of ONC010 by leveraging specialized expertise in polymer science and manufacturing.
In a separate announcement, the company also appointed Dave Antony as vice president of corporate finance. Antony brings more than 35 years of experience in financial planning, reporting, corporate governance, and public company advisory services, including leadership roles with TSX Venture Exchange advisory committees. Onco-Innovations stated that his background in capital markets and corporate finance is expected to support the company’s oncology-focused growth strategy and ongoing engagement with investors and other stakeholders.
The developments signal Onco-Innovations' commitment to advancing its pipeline and strengthening its financial leadership. For leaders in the business and technology sectors, these partnerships often translate into faster time-to-market for innovative cancer treatments, potentially impacting patient outcomes and creating value for stakeholders.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. More information about the company can be found at https://oncoinnovations.com/.
The full press release detailing these announcements is available at https://ibn.fm/JB4rY.
